Access to the PDF text

Free Article !

Archives of cardiovascular diseases
Volume 108, n° 12
pages 626-633 (décembre 2015)
Doi : 10.1016/j.acvd.2015.06.008
Received : 17 January 2015 ;  accepted : 22 June 2015
Benefit of endovascular stenting for aortic coarctation on systemic hypertension in adults
Bénéfices d’un stenting cardiovasculaire dans la coarctation aortique chez des adultes hypertendus

Tahir Hamid, Manish Motwani, Heiko Schneider, Jaspal Singh Dua, Andreas Hoschtitzky, Bernard Clarke, Vaikom S. Mahadevan
 Manchester Royal Infirmary, University of Central Manchester, NHS Foundation Trust, Manchester, UK 

Corresponding author. Division of Cardiology, UCSF, L524, 505 Parnassus Avenue, San Francisco, CA 94143, USA.

Endovascular stenting is a recognised treatment strategy for aortic coarctation (CoA) in adults. We assessed systemic hypertension control and the need for antihypertensive therapy after CoA stenting in adults.


Data were collected prospectively on 54 patients (36 men; mean age: 34±16 years) who underwent endovascular stenting for CoA over a 7-year period. Five patients were excluded as they did not attend follow-up appointments. Patients underwent clinical examination, including right arm systolic blood pressure (SBP) and 24-hour ambulatory blood pressure monitoring at baseline, 6–12 weeks and 9–12 months.


There was a significant fall in mean peak-to-peak systolic gradient (PG) across the CoA after stenting (26±11mmHg vs. 5±4mmHg; P <0.01). There were successive reductions in right arm SBP and ambulatory SBP at baseline, 6–12 weeks and 9–12 months post-procedure (right arm: 155±18mmHg vs. 137±17mmHg vs. 142±16mmHg, respectively; all P -values <0.01; ambulatory: 142±14mmHg vs. 132±16mmHg vs. 131±15mmHg, respectively; all P -values <0.01). Twenty-four patients had severe CoA (PG >25mmHg before stenting); baseline SBP was significantly higher in severe versus non-severe patients (160mmHg vs. 148mmHg; P =0.02). The absolute reduction in PG after stenting was significantly higher in the severe group (31±7mmHg vs. 14±5mmHg; P <0.0001), but there was no significant difference in SBP between groups at 6–12 weeks (141mmHg vs. 135mmHg; P =0.21) or 9–12 months (139mmHg vs. 139mmHg; P =0.96).


Endovascular stenting of CoA results in a significant reduction in SBP at 6–12 weeks, which is sustained at 9–12 months, with similar outcomes in severe and non-severe CoA groups.

The full text of this article is available in PDF format.

Le stenting endovasculaire est une stratégie thérapeutique validée de traitement de la coarctation aortique chez l’adulte. Nous avons évalué le contrôle de l’hypertension artérielle et la nécessité d’un traitement antihypertenseur chez des patients porteurs d’une coarctation aortique traités par stenting.


Les données ont été collectées de façon prospective chez 54 patients, 36 hommes, âge moyen de 34±16ans, qui ont bénéficié d’un stenting endovasculaire pour coarctation aortique pendant une période de suivi de 7ans. Cinq patients ont été exclus, car ils n’étaient pas suivis de façon régulière. Les patients ont été évalués cliniquement, avec mesures de la pression artérielle au bras droit ainsi qu’un enregistrement ambulatoire de la pression artérielle sur 24heures, à l’état basal, à 6–12 semaines et à 9–12 mois.


Nous avons observé une diminution significative du gradient intra-aortique pic à pic moyen après le stenting (26±11mmHg versus 5±4mmHg ; p <0,01). Nous avons observé une réduction significative de la pression artérielle au bras droit et de la pression artérielle ambulatoire à l’état basal, à 6–12 semaines et à 9–12 mois au décours de la procédure (bras droit : 155±18mmHg versus 137±17mmHg versus 142±16mmHg respectivement ; valeurs de p <0,01). Pour la pression artérielle ambulatoire, les chiffres sont respectivement de 142±14mmHg versus 132±16mmHg versus 131±15mmHg (valeurs de p <0,01). Vingt-quatre patients ayant une coarctation aortique sévère avec un gradient intra-aortique>25mmHg avant le stenting ont bénéficié de façon très significative de cette procédure de stenting ; la pression artérielle à l’état basal était significativement plus élevée que chez les patients ayant un gradient en deçà de 25mmHg (160mmHg versus 148mmHg ; p =0,02). La réduction absolue du gradient de pression aortique au décours du stenting était significativement plus important dans le groupe ayant à l’état basal la coarctation la plus sévère (31±7mmHg versus 14±5mmHg ; p <0,0001). Il n’y avait pas cependant de différence significative de pression artérielle systolique entre les groupes à 6–12 semaines (141mmHg versus 135mmHg ; p =0,21) ou à 9–12 mois (139mmHg versus 139mmHg ; p =0,96).


Le stenting endovasculaire de la coarctation aortique chez l’adulte conduit à une réduction significative du niveau de pression artérielle à 6–10 semaines, se maintient à 9–12 mois avec un suivi similaire qu’il s’agisse de patients ayant ou non une coarctation aortique sévère à l’état basal.

The full text of this article is available in PDF format.

Keywords : Aortic coarctation, Systemic hypertension, Coarctation stenting

Mots clés : Coarctation aortique, Hypertension artérielle systématique, Stenting pour coarctation

Abbreviations : AUC, CI, CoA, PG, ROC, SBP


Aortic coarctation (CoA) is a congenital narrowing of the upper descending thoracic aorta adjacent to the site of attachment of the ductus arteriosus (ligamentum arteriosum) [1]. CoA represents 5–10% of all congenital cardiac lesions [2]. CoA has a male predominance and has been associated with conditions that include gonadal dysgenesis (Turner's syndrome), Shone's complex, bicuspid aortic valve, intracranial aneurysms, patent ductus arteriosus, ventricular septal defect and mitral stenosis or regurgitation [1, 3]. If left untreated, CoA is associated with high morbidity and mortality [4, 5]. The first surgical repair for CoA was performed in 1945 [6]. Various surgical techniques were developed across age groups, including resection with end-to-end anastomosis, extended end-to-end anastomosis, end-to-side anastomosis, extra-anatomical bypass, tube graft replacement, patch augmentation and subclavian flap aortoplasty [1]. Surgical repair is performed depending on age of presentation, ranging from newborns to adults [7]. Patients can develop restenosis of the previously repaired CoA with the passage of time, because of fibrous scar tissue or residual ductal tissue contracting.

In 1982 [8], the first percutaneous balloon dilatation was successfully performed in an infant and, since then, has also been successfully performed in recurrent CoA [9, 10, 11]. While balloon dilatation showed promising results in the short-term, because of the elastic recoil properties of the aorta, restenosis was common, being reported in up to 20–30% of patients [10, 11]. In 1991, O’Laughlin et al. [12] successfully used balloon-expandable endovascular stents, and this technique is currently an established management strategy in adults with CoA [13, 14, 15, 16].

The main objectives of this study were to assess systemic hypertension outcomes and the need for antihypertensive therapy in adolescent and adult patients undergoing primary stenting for CoA.

Study population

The data were collected prospectively for 54 adolescent and adult patients who underwent transcatheter stenting of CoA over a 7-year period. These patients were followed up as part of a non-randomized observational protocol. Informed written consent was obtained from all patients before the stenting procedure, according to local guidelines. Patients were defined as being hypertensive if they had blood pressure readings (right upper limb) >140/90mmHg on more than one occasion at rest [17]. Blood pressure was measured at 6–12 weeks and 9–12 months at clinical follow-up, and included outpatient ambulatory blood pressure monitoring. Clinical blood pressure was measured 10minutes after arrival of the patient at the outpatient department, in an upright position in the right upper limb with an automated cuff.

Stent deployment technique

A single lead operator performed all procedures with either covered or uncovered stents, according to operator preference and angiographic findings. All procedures were performed under general anaesthesia. The covered stents used were the Cheatham Platinum (CP) stent™ (NuMED, Hopkinton, NY, USA) and the Adventa V12™ stent (Atrium, Mijdrecht, Netherlands); the uncovered stents used were the Max™ LD stent (EV3, Plymouth, MN, USA), the PALMAZ™ stent (Cordis [Johnson & Johnson], Roden, the Netherlands), the CP Stent™ (NuMED, Hopkinton, NY, USA) and the JOSTENT™ (Abbott Vascular Devices, Santa Clara, CA, USA). The balloons used for deployment of non-premounted stents included the balloon-in-balloon (BIB™; NuMED, Hopkinton, NY, USA) and Cristal™ balloons (Balt, Montmorency, France).

Vascular access was achieved from the femoral artery in all patients. Further arterial access was achieved using the right radial artery in all patients except one, in whom brachial artery access was obtained. In two patients, the CoA site could not be crossed from the femoral approach, and the wire was snared from the femoral artery after antegrade crossing of the coarctation from an upper limb vessel. Femoral arterial access sites were preclosed using a Perclose A-T™ or Proglide™ device (Abbott Vascular Devices, Santa Clara, CA, USA) in 49 (91%) patients. Patients received 5000IU heparin. Aortic pressures were simultaneously recorded in the ascending aorta and descending thoracic aorta to measure the peak-to-peak systolic gradient (PG) across the CoA segment. An aortic arch angiogram was taken in the left lateral and right anterior oblique views. Measurements were then obtained from the images, including the diameter of the aorta proximal and distal to the site of obstruction. The diameter of the balloon was chosen to equal that of the normal portion of the transverse arch or proximal isthmus at the level of the take off of the left subclavian artery.

The location of the CoA relative to landmarks within the chest was noted for reference during positioning and implantation. Implantation was performed using standard techniques. After successful deployment of the CoA stent, the femoral artery access site was closed with the Perclose A-T™ or Proglide™ preclosure device.

Major complications were defined as mortality or complications requiring surgical intervention – either cardiac or vascular – including the need for blood transfusions.

Statistical analysis

Analysis was performed using SPSS 17.0 (SPSS, Chicago, IL, USA). Group means were compared using paired or unpaired Student's t tests as appropriate. Absolute PG reduction (baseline PG – post-stenting PG) and percentage PG reduction ([absolute PG reduction/baseline PG]×100) were calculated for each procedure. The correlations between baseline PG and baseline systolic blood pressure (SBP), and between PG reduction (absolute and percentage change) and SBP reduction (baseline – post-stenting SBP) at 6–12 weeks and 9–12 months were assessed using Pearson's correlation coefficients. Additionally, the predictive accuracy of absolute and percentage PG reduction to predict adequate SBP control (<140/90mmHg) was determined using receiver-operating characteristic (ROC) analysis, and expressed as area under the curve (AUC). To determine statistical significance, various AUCs were compared with 0.5 and their 95% confidence intervals (CIs) calculated. Based on invasive haemodynamic data we divided patients into severe CoA (PG >25mmHg) and non-severe CoA (PG ≤25mmHg) groups for comparison. All statistical tests were two-tailed and a P -value <0.05 was considered significant. Stepwise univariate and multivariable logistic regression analyses were performed for the outcome of SBP <140mmHg at 12 months using the following variables: age, sex, preprocedural SBP, preprocedural PG, post-procedural PG, absolute and percentage PG reduction. An alpha level of 0.05 was used for entry into multivariable analysis.

Stepwise logistic regression

On univariate logistic regression, only preprocedural SBP significantly predicted a 12-month outcome of SBP <140mmHg (P <0.05). All the other variables tested failed to reach significance (all P -values >0.05). Multivariable analysis was therefore not performed.

Study population

Over a 7-year period, a total of 54 consecutive patients underwent CoA stenting. Five patients were excluded, as they did not attend follow-up appointments within the specified time periods for blood pressure monitoring. Forty-nine patients had complete measurements; their mean age was 34±16 years (range: 15–72 years). Patient demographics, lesion characteristics and associated conditions are given in Table 1.

Patients were followed up for 24±17 months (range: 3–65 months, median: 17 months). A total of 17/54 (31%) patients had a follow-up angiogram, while the rest had non-invasive assessment using a computed tomographic scan. One patient had successful redilatation of his stent 28 months later for stent recoil with increasing gradients. No other patient required reintervention for the CoA, and there was no evidence of aneurysm formation. One patient needed deployment of a covered stent because of fracture of stent struts in the previously deployed stent. Two patients underwent additional cardiac procedures unrelated to the CoA stenting procedure, including percutaneous aortic balloon valvuloplasty for aortic stenosis (bicuspid aortic valve) and device closure of a left-sided ascending vein for partial anomalous pulmonary venous drainage [17].

One patient had a stroke 5 months after the procedure, was thrombolysed and made a satisfactory recovery. One patient underwent successful surgical aortic valve replacement and one patient underwent mastectomy for carcinoma of breast in the follow-up period. There was one death in the follow-up period resulting from non-cardiac causes.

Procedural data

Previous balloon dilatations had been performed in 10 patients. Two patients had undergone three previous balloon dilatation procedures each. None of these was performed as part of the stenting procedure. Covered stents were used in 40 (74%) patients: the CP Stent™ was used in 24/54 (44%) patients and the Adventa V12™ stent was used in 16/54 (30%) patients. Uncovered stents were used in 14 (26%) patients: the CP Stent™, the Max LD™ and the JOSTENT™ (Abbott Vascular Devices, Santa Clara, CA, USA) were used in 11 patients, 2 patients and 1 patient, respectively. The stent length varied from 28 to 40mm. In 40/54 (74%) patients the femoral access site was closed using a preclosure technique with a Perclose™ closure device. Femoral artery sheath sizes ranged from 10–14 Fr (French).


There was no procedure-related mortality or need for emergency cardiac or vascular surgery. All patients were mobilized within 6hours after the procedure, except one patient who had a femoral artery dissection, which was successfully managed conservatively. None of the patients had an endovascular leak after intervention. Major vascular access site complication was seen in one additional patient, who developed an arteriovenous fistula that was diagnosed 2 weeks after the stenting procedure and required vascular surgical repair. There was one non-cardiac related death, but no cardiac mortality in the follow-up period. One patient with a very tortuous aorta had stent embolization; this stent was safely redeployed in the descending abdominal aorta.

Peak-to-peak systolic gradients

There was a weak but significant linear correlation between baseline PG and baseline SBP (r =0.45; P =0.001; Figure 1). There was a significant fall in PG across the CoA after stenting, from 26±11mmHg (range: 10–50mmHg) to 5±4mmHg (range: 0–20mmHg; P <0.01). The changes in PG for individual lesions are shown in Figure 2.

Figure 1

Figure 1. 

There was a weak but significant linear correlation between baseline peak gradient (PG) across aortic coarctation and baseline systolic blood pressure (SBP) in the right arm (r =0.45; P =0.001). The line of best fit is shown in black.


Figure 2

Figure 2. 

Individual changes in peak gradient across aortic coarctation immediately after stenting.


Blood pressure outcomes

There was a significant reduction in baseline SBP from 155±18 to 137±17mmHg at 6–12 weeks (P <0.01; n =50) and to 142±16mmHg (P =0.001) at 9–12 months (n =47) after stenting. There was a significant reduction in ambulatory 24-hour SBP from 142±14mmHg at baseline to 132±16mmHg at 6 weeks (P <0.01; n =41) and to 131±15mmHg at 9–12 months (P =0.003; n =33) after stenting.

There was no significant difference in the mean number of antihypertensive medications used before and after stenting in the study population overall (1.9±0.7 vs. 1.7±0.6; P =0.68), or specifically in those patients on antihypertensive medication at baseline (n =35; 1.8±0.7 vs. 1.8±0.7; P =0.38). Fifteen patients were normotensive at baseline without needing antihypertensive treatment. Similarly, four patients had clinical SBP ≥150mmHg preprocedure and preferred to wait for the intervention procedure before starting antihypertensive treatment. These four patients went on to have antihypertensive therapy at 12-month follow-up after CoA stenting, despite an excellent gradient reduction (residual gradient <10mmHg) in all cases, as their blood pressure was not in the target range (140/90mmHg) at 6-week follow-up. One of these patients also had Turner's syndrome with a hypoplastic arch.

The antihypertensive treatments used included beta-blockers, angiotensin-converting enzyme inhibitors and calcium channel blockers.

There were no significant correlations between reduction in PG after stenting (absolute or percentage change) and reductions in SBP at 6–12 weeks or at 9–12 months compared with baseline (Table 2). On ROC analysis, neither the absolute nor the percentage PG reduction after stenting significantly predicted adequate control of SBP at 6 weeks (AUC 0.62 and 0.51, respectively) or at 6 months (AUC 0.47 and 0.54, respectively; all 95% CIs traversed zero and all P -values were >0.10; Figure 3).

Figure 3

Figure 3. 

On receiver-operating characteristic analysis, neither the absolute (A, B) nor the percentage reduction (C, D) in peak gradient (PG) across aortic coarctation after stenting significantly predicted adequate control of systolic blood pressure (SBP) at 6 weeks or 6 months. AUC: area under the curve; CI: confidence interval.


Severe versus non-severe aortic coarctation

Twenty-four patients were classified as having severe CoA (PG >25mmHg) and 25 as having non-severe CoA (PG ≤25mmHg) before stenting. The severe CoA group had a significantly higher SBP at baseline compared with the non-severe group (160 vs. 148mmHg; P =0.02). After stenting, the absolute reduction in PG was significantly higher in the severe versus the non-severe group (31±7mmHg vs. 14±5mmHg; P <0.0001), but there was no significant difference in the percentage PG change between the two groups (84±12% vs. 77±19%; P =0.12). At 6 weeks, there was no significant difference in SBP between the severe and non-severe groups (141mmHg vs. 135mmHg; P =0.21), and this remained the case at 9–12 months (139mmHg vs. 139mmHg; P =0.96).


The management of CoA is mainly focused on gradient reduction, and the effect on hypertension, especially in adults, is not well described. This study demonstrates that transcatheter treatment for CoA in adolescents and adults with primary stenting results in immediate and sustained haemodynamic benefits. Specifically, the main findings were that there was a significant immediate reduction in absolute and percentage PG across the CoA after stenting in keeping with previous studies [14, 16, 18, 19, 20], which translated into a significant reduction in SBP at 6 weeks and 9–12 months, but that there was a need to maintain medical therapy. Another important finding was that the SBP profiles of severe and non-severe CoA seem to equilibrate at 6 weeks post-procedure, and this was maintained at 9–12 months, suggesting that both groups may follow a similar risk profile after intervention rather than continuing to diverge. This suggests that patients with non-severe CoA, as defined in this study, may derive benefit in terms of hypertension control with stenting of aortic coarctation, but this will require further large-scale clinical validation and a longer follow-up duration. Finally, the study also showed that the initial PG reduction (absolute or percentage change) is not an accurate predictor of whether normal SBP (<140/90) will be achieved in the long-term, and that other factors therefore need to be considered and studied in the future.

Arterial hypertension has been associated with increased morbidity and mortality from cardiovascular disease [21]. A study by Hager et al. [22] (n =404) showed persistent hypertension in patients who underwent surgical repair in >50% of patients at a follow-up of 27 years. Our study showed significant improvement in hypertension control after stenting in the immediate period, which persisted at 1 year. Persistent hypertension after CoA repair in the presence or absence of residual stenosis has been reported [18], and was also seen in our patients. While there was a trend towards a decrease in the number of antihypertensive medications after stenting, this did not reach significance. The majority of our patients continued antihypertensive therapy for optimal control, as has been described previously [13, 15]. The residual prevalence of hypertension after CoA stenting may be multifactorial, including morphology of the arch, age, poor arterial compliance, the change in target blood pressure guidance [23, 24, 25] and the effect of recurrent CoA. Similarly, our results showed that those patients who were not on any medication before intervention remained normotensive, with the need for antihypertensive medication in only four patients. Of those with established hypertension, five had their antihypertensive treatments stopped, indicating that it is may be possible to cease therapy with antihypertensive medication after stenting.

There is evidence in the adult literature that 24-hour blood pressure is a better predictor of end organ damage, and therefore provides a better measure of blood pressure than casual readings [26]. Our study demonstrated improvement in 24-hour blood pressure compared with baseline, which was sustained at 9–12 months, and it is possible that this may be of prognostic benefit in the long-term.

Surgery for CoA and recurrent CoA has been associated with complications, including death, stroke, infection, true and false aneurysm formation, rupture of the anastomosis causing a pseudoaneurysm, spinal cord damage (including paraplegia; 0.3%), unusual gait and aortic dissection and vocal cord palsy [27, 28, 29, 30]. Similarly, there is a risk of occlusion of the left subclavian artery or occlusion of other branches of the aorta [31] with covered stents. Strut fracture has been reported with uncovered CoA stents [32, 33, 34], as well as aortic dissection or rupture. One of our patients developed a strut fracture in a previously implanted stent, which was successfully treated with implantation of a covered CP Stent™.

The majority of our patients underwent stenting using a covered stent, which may decrease but not eliminate the risk of aortic perforation [35]. Previous studies have demonstrated the safety of CoA stenting in children [25, 36]. A review study (comparison between angioplasty [n =633] and surgery [n =213]) by Carr [37] showed a lower incidence of restenosis and recurrence in surgically treated patients, while CoA stenting has been associated with the lowest morbidity. Currently, based on the available literature [13, 14, 16, 18, 19, 20], primary stent deployment in native or recurrent CoA patients may be considered as first-line therapy in most adolescent and adult patients with CoA.

Our patients underwent additional procedures after CoA stenting, including percutaneous aortic balloon valvuloplasty for aortic stenosis and partial anomalous pulmonary venous drainage device closure [38], aortic valve replacement and mastectomy for carcinoma of breast, without any cardiovascular issues related to the CoA.

Study limitations

This was a cohort study, reflecting the fact that these data are derived from real-world practice in a selected group of patients. There was no controlled or regulated antihypertensive regimen or strategy (i.e. clinician choice was used in the prescription of antihypertensive treatment). We did not have a control arm comprising medical therapy alone. As many patients were referred from outside hospitals to our institution for specialist procedural treatment, additional background data on the study group, including duration of hypertension, left ventricular hypertrophy and renin/aldosterone status, was not complete in all patients to include in the analyses. As it generally takes longer than the presented 12 months of data to safely scale down antihypertensive treatment and to reassess for long-term success and freedom from hypertension treatment, such analyses are the subject of ongoing work to be reported in the future.


This study demonstrates that stenting of both native and recurrent CoA in adults results in a significant reduction in SBP 6 weeks after the procedure, which is sustained after a year. While there is a continuing need for antihypertensive therapy, even patients with non-severe CoA undergoing stenting appear to benefit from better control of systemic hypertension.

Disclosure of interest

The authors declare that they have no competing interest.Sources of funding: No grants/finances were required for this study.


Deanfield J.E., Yates R., Meijboom F.J., Mulder B.J.M. Congenital heart disease in children and adults The ESC textbook of cardiovascular medicine Oxford: OUP (2009).  313-366
Kaemmerer H. Aortic coarctation and interrupted aortic arch Diagnosis and management of adult congenital heart disease New York: Churchill Livingstone (2003).  254
Levine J.C., Sanders S.P., Colan S.D., Jonas R.A., Spevak P.J. The risk of having additional obstructive lesions in neonatal coarctation of the aorta Cardiol Young 2001 ;  11 : 44-53 [cross-ref]
Campbell M. Natural history of coarctation of the aorta Br Heart J 1970 ;  32 : 633-640 [cross-ref]
Warnes C.A., Williams R.G., Bashore T.M., and al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease) Circulation 2008 ;  118 : e714-e833
Crafoord C., Nylin G. Congenital coarctation of the aorta and its surgical treatment J Thorac Surg 1945 ; 347-361
Wood A.E., Javadpour H., Duff D., Oslizlok P., Walsh K. Is extended arch aortoplasty the operation of choice for infant aortic coarctation? Results of 15 years’ experience in 181 patients Ann Thorac Surg 2004 ;  77 : 1353-1357[discussion 7–8].
Singer M.I., Rowen M., Dorsey T.J. Transluminal aortic balloon angioplasty for coarctation of the aorta in the newborn Am Heart J 1982 ;  103 : 131-132 [cross-ref]
Hijazi Z.M., Fahey J.T., Kleinman C.S., Hellenbrand W.E. Balloon angioplasty for recurrent coarctation of aorta. Immediate and long-term results Circulation 1991 ;  84 : 1150-1156 [cross-ref]
Mann C., Goebel G., Eicken A., and al. Balloon dilation for aortic recoarctation: morphology at the site of dilation and long-term efficacy Cardiol Young 2001 ;  11 : 30-35
Yetman A.T., Nykanen D., McCrindle B.W., and al. Balloon angioplasty of recurrent coarctation: a 12-year review J Am Coll Cardiol 1997 ;  30 : 811-816 [cross-ref]
O’Laughlin M.P., Perry S.B., Lock J.E., Mullins C.E. Use of endovascular stents in congenital heart disease Circulation 1991 ;  83 : 1923-1939 [cross-ref]
Bentham J.R., English K., Ballard G., Thomson J.D. Effect of interventional stent treatment of native and recurrent coarctation of aorta on blood pressure Am J Cardiol 2013 ;  111 : 731-736 [inter-ref]
Harrison D.A., McLaughlin P.R., Lazzam C., Connelly M., Benson L.N. Endovascular stents in the management of coarctation of the aorta in the adolescent and adult: one-year follow-up Heart 2001 ;  85 : 561-566 [cross-ref]
Mahadevan V.S., Vondermuhll I.F., Mullen M.J. Endovascular aortic coarctation stenting in adolescents and adults: angiographic and hemodynamic outcomes Catheter Cardiovasc Interv 2006 ;  67 : 268-275 [cross-ref]
Marshall A.C., Perry S.B., Keane J.F., Lock J.E. Early results and medium-term follow-up of stent implantation for mild residual or recurrent aortic coarctation Am Heart J 2000 ;  139 : 1054-1060 [inter-ref]
Mancia G., Fagard R., Narkiewicz K., and al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 2013 ;  34 : 2159-2219
Eicken A., Pensl U., Sebening W., and al. The fate of systemic blood pressure in patients after effectively stented coarctation Eur Heart J 2006 ;  27 : 1100-1105
Hamdan M.A., Maheshwari S., Fahey J.T., Hellenbrand W.E. Endovascular stents for coarctation of the aorta: initial results and intermediate-term follow-up J Am Coll Cardiol 2001 ;  38 : 1518-1523 [cross-ref]
Magee A.G., Brzezinska-Rajszys G., Qureshi S.A., and al. Stent implantation for aortic coarctation and recoarctation Heart 1999 ;  82 : 600-606 [cross-ref]
Stamler J., Stamler R., Neaton J.D. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data Arch Intern Med 1993 ;  153 : 598-615 [cross-ref]
Hager A., Kanz S., Kaemmerer H., Schreiber C., Hess J. Coarctation long-term assessment (COALA): significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material J Thorac Cardiovasc Surg 2007 ;  134 : 738-745
Drozda J., Messer J.V., Spertus J., and al. ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement Circulation 2011 ;  124 : 248-270
Krause T., Lovibond K., Caulfield M., McCormack T., Williams B.Guideline Development G Management of hypertension: summary of NICE guidance BMJ 2011 ;  343 : d4891
Morgan G.J., Lee K.J., Chaturvedi R., Bradley T.J., Mertens L., Benson L. Systemic blood pressure after stent management for arch coarctation implications for clinical care JACC Cardiovasc Interv 2013 ;  6 : 192-201 [cross-ref]
Parati G., Pomidossi G., Albini F., Malaspina D., Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension J Hypertens 1987 ;  5 : 93-98 [cross-ref]
Keen G. Spinal cord damage and operations for coarctation of the aorta: aetiology, practice, and prospects Thorax 1987 ;  42 : 11-18 [cross-ref]
Kenny D., Margey R., Turner M.S., Tometzki A.J., Walsh K.P., Martin R.P. Self-expanding and balloon expandable covered stents in the treatment of aortic coarctation with or without aneurysm formation Catheter Cardiovasc Interv 2008 ;  72 : 65-71
Ross J.K., Monro J.L., Sbokos C.G. Late complications of surgery for coarctation of the aorta Thorax 1975 ;  30 : 31-39 [cross-ref]
Varejka P., Lubanda J.C., Prochazka P., and al. Late complication of surgical repair of aortic coarctation: ruptured pseudoaneurysm of the aorta treated by thoracic endovascular aortic repair J Mal Vasc 2010 ;  35 : 189-193 [inter-ref]
Forbes T.J., Garekar S., Amin Z., and al. Procedural results and acute complications in stenting native and recurrent coarctation of the aorta in patients over 4 years of age: a multi-institutional study Catheter Cardiovasc Interv 2007 ;  70 : 276-285 [cross-ref]
Pedra C.A., Fontes V.F., Esteves C.A., and al. Use of covered stents in the management of coarctation of the aorta Pediatr Cardiol 2005 ;  26 : 431-439 [cross-ref]
Qureshi S.A. Use of covered stents to treat coarctation of the aorta Korean Circ J 2009 ;  39 : 261-263 [cross-ref]
Tanous D., Collins N., Dehghani P., Benson L.N., Horlick E.M. Covered stents in the management of coarctation of the aorta in the adult: initial results and 1-year angiographic and hemodynamic follow-up Int J Cardiol 2010 ;  140 : 287-295 [cross-ref]
Collins N., Mahadevan V., Horlick E. Aortic rupture following a covered stent for coarctation: delayed recognition Catheter Cardiovasc Interv 2006 ;  68 : 653-655 [cross-ref]
Thanopoulos B.D., Giannakoulas G., Giannopoulos A., Galdo F., Tsaoussis G.S. Initial and six-year results of stent implantation for aortic coarctation in children Am J Cardiol 2012 ;  109 : 1499-1503 [inter-ref]
Carr J.A. The results of catheter-based therapy compared with surgical repair of adult aortic coarctation J Am Coll Cardiol 2006 ;  47 : 1101-1107 [cross-ref]
Mamas M.A., Clarke B., Mahadevan V.S. Percutaneous treatment of dual pulmonary venous drainage and coarctation of the aorta in a single patient Exp Clin Cardiol 2010 ;  15 : 11-13

© 2015  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline